No, GLP-1 patches are not currently licensed or available in the UK
(This estimate could be conservative to the extent that not all beneficiaries with obesity or overweight may have a claims-based diagnosis.) However, the potentially eligible population for the Medicare GLP-1 Bridge is not as broad as if the program were targeted to all people with Medicare with obesity or overweight
Anyway, it should be emphasized that the encouraging results from basic science were not yet translated into clinical evidence, probably due the multiple and pleiotropic enzymatic effects of DPP4 inhibition
Otherwise, the medication is a flat $140 cash price
Using chemogenetic, optogenetic, and viral tracing strategies to study how GLP-1 signals in the brain impact liver fibrosis and inflammation is an area of intense basic investigation
In a separate 36-week phase 2 trial in 281 T2D patients treated with up to 12mg retatrutide weekly, researchers observed significant reductions in HbA1c